Analyst Confident In Moderna’s Cancer Vaccine But Highlights Other Challenges

Moderna misses Q4 EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake challenges. Latest Ratings for MRNA Date Firm Action From To Mar 2022 Deutsche Bank Maintains Hold Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 SVB Leerink Maintains Underperform View More Analyst Ratings for MRNA View the…

Read More